Your browser is no longer supported. Please, upgrade your browser.
Benitec Biopharma Inc.
Index- P/E- EPS (ttm)-3.23 Insider Own27.04% Shs Outstand4.30M Perf Week-1.88%
Market Cap18.85M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float3.98M Perf Month-8.55%
Income-10.70M PEG- EPS next Q- Inst Own13.50% Short Float7.05% Perf Quarter-0.71%
Sales0.05M P/S392.68 EPS this Y- Inst Trans58.00% Short Ratio0.10 Perf Half Y53.87%
Book/sh3.40 P/B1.23 EPS next Y- ROA-56.80% Target Price- Perf Year-52.45%
Cash/sh- P/C- EPS next 5Y- ROE-63.00% 52W Range2.30 - 12.52 Perf YTD39.00%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-66.69% Beta1.69
Dividend %- Quick Ratio18.50 Sales past 5Y-50.40% Gross Margin- 52W Low81.30% ATR0.52
Employees13 Current Ratio18.50 Sales Q/Q-98.70% Oper. Margin- RSI (14)44.99 Volatility8.02% 9.36%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.05 Prev Close4.26
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume2.82M Price4.17
Recom3.00 SMA20-12.47% SMA50-2.92% SMA200-7.95% Volume136,923 Change-2.11%
Oct-05-20Downgrade Ladenburg Thalmann Buy → Neutral
Apr-20-20Initiated Ladenburg Thalmann Buy $14
Feb-26-16Downgrade Maxim Group Buy → Hold
Dec-31-15Reiterated Maxim Group Buy $23 → $14
Sep-16-15Reiterated Maxim Group Buy $4 → $23
Apr-27-21 09:55PM  
Mar-23-21 12:18PM  
Feb-24-21 09:26AM  
Dec-07-20 02:33PM  
Dec-02-20 12:06AM  
Oct-06-20 04:05PM  
Oct-02-20 09:05AM  
Sep-23-20 04:54PM  
Sep-01-20 08:15AM  
Jul-08-20 08:00AM  
Apr-20-20 06:49AM  
Apr-15-20 08:52AM  
Apr-14-20 09:28PM  
Mar-30-20 10:09AM  
Mar-26-20 09:44AM  
Feb-27-20 06:18PM  
Jan-31-20 08:08AM  
Nov-27-19 08:00AM  
Nov-17-19 07:02PM  
Nov-15-19 07:00AM  
Oct-31-19 08:30AM  
Sep-30-19 09:24AM  
Sep-19-19 09:15AM  
Sep-16-19 08:00AM  
Sep-15-19 09:49PM  
Jul-31-19 08:30AM  
Jul-11-19 11:34PM  
Jun-06-19 08:09AM  
May-08-19 08:01PM  
Mar-06-19 09:52PM  
Jan-29-19 09:46PM  
Dec-21-18 10:10AM  
Nov-23-18 12:01AM  
Nov-15-18 07:35AM  
Sep-19-18 08:00AM  
Jul-14-18 02:02PM  
Jul-10-18 05:15PM  
Jul-09-18 11:04AM  
Jul-08-18 08:59PM  
May-31-18 08:00AM  
May-15-18 08:00AM  
May-03-18 08:00AM  
Apr-24-18 08:00AM  
Mar-05-18 08:00AM  
Feb-22-18 08:30AM  
Jan-23-18 04:17PM  
Jan-16-18 08:00AM  
Nov-27-17 09:30AM  
Oct-18-17 07:45AM  
Sep-05-17 02:54PM  
Sep-01-17 04:00PM  
Aug-08-17 08:30AM  
Apr-05-17 07:30AM  
Apr-04-17 04:40PM  
Mar-27-17 09:30AM  
Mar-13-17 06:00AM  
Feb-16-17 08:00AM  
Feb-03-17 09:45AM  
Feb-02-17 12:05PM  
Jan-30-17 08:00AM  
Jan-18-17 09:30AM  
Jan-17-17 11:05AM  
Dec-23-16 06:00AM  
Dec-20-16 07:00AM  
Oct-24-16 07:10PM  
Sep-23-16 11:34AM  
Aug-10-16 05:00AM  
May-24-16 04:45AM  
May-17-16 05:00AM  
Apr-25-16 08:30AM  
Mar-08-16 08:16AM  
Mar-07-16 02:29PM  
Feb-26-16 07:26AM  
Feb-25-16 10:13PM  
Jan-29-16 07:36PM  
Dec-10-15 07:51PM  
Dec-08-15 05:05PM  
Dec-07-15 08:00AM  
Oct-29-15 11:13AM  
Oct-22-15 08:00AM  
Oct-19-15 07:30AM  
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. The company was founded in 1995 and is headquartered in Hayward, California.